Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181150
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mora Luján, José María | - |
dc.contributor.author | Tuells, Manel | - |
dc.contributor.author | Montero Saez, Abelardo | - |
dc.contributor.author | Formiga Pérez, Francesc | - |
dc.contributor.author | Homs Martí, Narcís | - |
dc.contributor.author | Albà-Albalate, Joan | - |
dc.contributor.author | Corbella, Xavier | - |
dc.contributor.author | Rubio-Rivas, Manuel | - |
dc.date.accessioned | 2021-11-08T18:17:57Z | - |
dc.date.available | 2021-11-08T18:17:57Z | - |
dc.date.issued | 2021-09-28 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/181150 | - |
dc.description.abstract | Corticosteroids are largely recommended in patients with severe COVID-19. However, evidence to support high-dose methylprednisolone (MP) pulses is not as robust as that demonstrated for low-dose dexamethasone (DXM) in the RECOVERY trial. This is a retrospective cohort study on severe, non-critically ill patients with COVID-19, comparing 3-day MP pulses ≥ 100 mg/day vs. DXM 6 mg/day for 10 days. The primary outcome was in-hospital mortality, and the secondary outcomes were need of intensive care unit (ICU) admission or invasive mechanical ventilation (IMV). Propensity-score matching (PSM) analysis was applied. From March 2020 to April 2021, a total of 2,284 patients were admitted to our hospital due to severe, non-critically ill COVID-19, and of these, 189 (8.3%) were treated with MP, and 493 (21.6%) with DXM. The results showed that patients receiving MP showed higher in-hospital mortality (31.2% vs. 17.8%, p < 0.001), need of ICU admission (29.1% vs. 20.5%, p = 0.017), need of IMV (25.9% vs. 13.8, p < 0.001), and median hospital length of stay (14 days vs. 11 days, p < 0.001). Our results suggest that treatment with low-dose DXM for 10 days is superior to 3 days of high-dose MP pulses in preventing in-hospital mortality and need for ICU admission or IMV in severe, non-critically ill patients with COVID-19. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm10194465 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2021, vol. 10, num. 19, p. 4465 | - |
dc.relation.uri | https://doi.org/10.3390/jcm10194465 | - |
dc.rights | cc-by (c) Mora Luján, José María et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Corticosteroides | - |
dc.subject.classification | Mortalitat | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Adrenocortical hormones | - |
dc.subject.other | Mortality | - |
dc.title | High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 714461 | - |
dc.date.updated | 2021-11-08T18:17:57Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34640481 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
714461.pdf | 2.04 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License